Literature DB >> 11934561

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

Michael J McCluskie1, Risini D Weeratna, Paul J Payette, Heather L Davis.   

Abstract

Synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs (CpG ODN) are potent adjuvants to protein antigens administered by parenteral or mucosal routes to BALB/c mice. To date, there have been no studies using combined parenteral/mucosal approaches with CpG DNA as adjuvant. In this study we evaluated different parenteral prime-mucosal boost and mucosal prime-parenteral boost strategies using hepatitis B surface antigen (HBsAg) alone or with different adjuvants: aluminum hydroxide (alum), cholera toxin (CT), CpG ODN. In addition, since CpG ODN has previously been shown to act synergistically with other adjuvants after parenteral or mucosal delivery, we also evaluated adjuvant combinations: alum+CpG ODN and CT+CpG ODN. The effects of adjuvant and administration strategy on systemic and mucosal humoral responses were measured, as well as cell-mediated immune responses (cytotoxic T lymphocyte activity). These results were compared to parenteral only or mucosal only strategies. Our findings demonstrate that parenteral immunization can prime for mucosal responses even when different lymph nodes were being targeted. HBsAg-specific immune responses (IgG in plasma, cytotoxic T lymphocytes) induced by parenteral prime could all be significantly enhanced by mucosal boosting and despite the fact that intramuscular immunization alone could not induce mucosal IgA, it could prime for a subsequent mucosal boost. In addition, the presence of adjuvant at time of boosting could influence the nature of subsequent immune responses (Th1 vs. Th2). Mice primed intranasally could have their systemic immune responses boosted with a parenteral administration and it was also possible to enhance mucosal responses induced by intranasal prime with an intramuscular boost.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934561     DOI: 10.1111/j.1574-695X.2002.tb00551.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  26 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

3.  Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Authors:  Valeria Alcon; Maria Baca-Estrada; Marco Vega-Lopez; Philip Willson; Lorne A Babiuk; Praveen Kumar; Rolf Hecker; Marianna Foldvari
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

4.  Generation and characterization of recombinant feline beta-galactosidase for preclinical enzyme replacement therapy studies in GM1 gangliosidosis.

Authors:  Tatiana I Samoylova; Douglas R Martin; Nancy E Morrison; Misako Hwang; Anna M Cochran; Alexandre M Samoylov; Henry J Baker; Nancy R Cox
Journal:  Metab Brain Dis       Date:  2008-04-18       Impact factor: 3.584

Review 5.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

6.  Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization.

Authors:  Daniel R Tonkin; Patricia Jorquera; Tracie Todd; Clayton W Beard; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

7.  A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Authors:  Chad E Mire; Joan B Geisbert; Krystle N Agans; Yan-Ru Feng; Karla A Fenton; Katharine N Bossart; Lianying Yan; Yee-Peng Chan; Christopher C Broder; Thomas W Geisbert
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis.

Authors:  Douglas R Martin; Brigitte A Rigat; Polly Foureman; G S Varadarajan; Misako Hwang; Barbara K Krum; Bruce F Smith; John W Callahan; Don J Mahuran; Henry J Baker
Journal:  Mol Genet Metab       Date:  2008-03-18       Impact factor: 4.797

9.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

10.  Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations.

Authors:  Michael Vajdy; Manmohan Singh; Mildred Ugozzoli; Maylene Briones; Elawati Soenawan; Lina Cuadra; Jina Kazzaz; Paolo Ruggiero; Samuele Peppoloni; Francesco Norelli; Giuseppe del Giudice; Derek O'Hagan
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.